On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
Cephalalgia
; 3 Suppl 1: 146-50, 1983 Aug.
Article
em En
| MEDLINE
| ID: mdl-6616596
ABSTRACT
With the combined pharmacokinetic-pharmacodynamic approach, the bioavailability and venoconstrictor effects of two DHE formulations (programmed release capsules and oral solution) have been compared after acute oral dose administrations in the healthy volunteer subjects. The bioavailability of DHE from programmed release capsules has been significantly greater than that shown by the oral solution. DHE capsules formulation has seemed to provide appropriate plasma concentrations for at least 10 h after administration. That may well account for its efficacy in the treatment of morning migraine.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Di-Hidroergotamina
/
Transtornos de Enxaqueca
Idioma:
En
Ano de publicação:
1983
Tipo de documento:
Article